Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    20647199 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Enrolling by invitation Rituximab for ANCA-associated Vasculitis (RAVE) Long-Term Follow-Up Study
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Other: Observational
2 Completed
Has Results
Rituximab for the Treatment of Wegener's Granulomatosis and Microscopic Polyangiitis
Conditions: Vasculitis;   Wegener's Granulomatosis;   Microscopic Polyangiitis
Interventions: Drug: Rituximab plus cyclophosphamide placebo (rituximab group);   Drug: Cyclophosphamide plus rituximab placebo (control group);   Drug: Azathioprine;   Drug: Methylprednisolone (or other glucocorticoid);   Drug: Prednisone
3 Recruiting Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing
Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Intervention: Drug: Rituximab
4 Not yet recruiting Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Condition: Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions: Drug: Rituximab;   Other: Placebo
5 Recruiting Low-dose Glucocorticoid Vasculitis Induction Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Drug: Rituximab;   Drug: Glucocorticoids
6 Active, not recruiting Rituximab Vasculitis Maintenance Study
Conditions: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis;   Microscopic Polyangiitis;   Wegener Granulomatosis
Interventions: Biological: Rituximab;   Drug: Azathioprine

Study has passed its completion date and status has not been verified in more than two years.